We have described previously in the Finnish population an inactivating point mutation ( 566 C3 T) in the human FSH receptor (FSHR) gene. In women, this mutation causes hypergonadotropic ovarian failure with arrest of follicular maturation and infertility, whereas in men, there is variable suppression of spermatogenesis, but no absolute infertility. To determine whether the same FSHR mutation occurs in other populations, its frequency was determined in Finland, Switzerland, Denmark, and the Chinese population of Singapore. The mutation was screened for using genomic DNA extracted from whole blood or dried blood spots. Exon 7 of the FSHR gene was first amplified using a pair of biotinylated primers. The PCR products were then immobilized on streptavidin-coated microtitration wells and hybridized using short allele-specific oligonucleotide probes labeled with europium. Time-resolved fluorometry was used for europium signal detection. To test the reliability of this method, 40 isolated DNA samples and 35 dried blood spot samples were blindly tested for the 566 C3 T FSHR mutation. The analyses yielded identical results with denaturing gradient gel electrophoresis and allele-specific restriction enzyme digestion of the same samples, thus demonstrating the reliability of the tested method. Automation of this procedure allows the screening of large numbers of samples, which was subsequently carried out to investigate the frequency of the 566 C3 T mutation in the study populations. A total of 4981 samples from the above-mentioned 4 countries were analyzed. The frequency of the 566 C3 T mutation was 0.96% for all Finnish samples (n ϭ 1976), with a strong enrichment of the mutant allele in the northeastern part of the country. Only 1 mutation carrier was identified in the samples from Switzerland (n ϭ 1162), whereas none was found in samples from Denmark (n ϭ 1094) and the Singapore Chinese (n ϭ 540). These results suggest that the 566 C3 T mutation of the FSHR gene is enriched in Finland, but is uncommon in other populations. (J Clin Endocrinol Metab 83: 4338 -4343, 1998) A 566 C3 T point mutation in exon 7 of the FSH receptor (FSHR) gene, resulting in an Ala to Val change at residue 189 of the extracellular ligand-binding domain of the FSHR, was recently found in hypergonadotropic ovarian failure with normal female karyotype (1). These studies were initiated in Finland with a populationbased investigation of women born between 1950 -1976, and a total of 75 females with ovarian failure and primary or early secondary amenorrhea were identified (2). Of these, 22 women were found to have the above-mentioned point mutation. The inactivation of FSH action caused by this mutation resulted in the arrest of follicular maturation and infertility in females (3). In 5 males homozygous for the same mutation, variable suppression of spermatogenesis, but no azoospermia or absolute infertility, was found (4). Detection of this mutation is important because it explains the pathogenesis of hypergonadotropic ovarian failure and suppressed spermatogenesis in this special group of patients, thus facilitating the diagnosis of infertility and the choice of therapy. Until the present study, nothing was known about the occurrence of the 566 C3 T FSHR mutation in other populations.
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Many hereditary diseases are caused by single point mutations, and special methods are needed for their diagnosis, especially upon large scale screening. Molecular analysis methods such as allele-specific oligonucleotide hybridization (5), oligonucleotide ligation assay (6, 7), use of allelespecific oligonucleotide primers (8, 9) , competitive oligonucleotide priming (8) , PCR amplification of specific alleles (10) , chemical mismatch analysis (11) , sequencing (12) , and minisequencing (13) have been developed for this purpose. Our aim was to develop an assay based on a sensitive nonradioactive detection method with an easy to use assay for-mat for large scale screening of the inactivating FSHR gene point mutation ( 566 C3 T) to examine its allelic frequency in various populations.
Time-resolved fluorometry has been used in the signal detection of DNA assays for the detection of mutations by allele-specific amplification and allele-specific hybridization (14 -21) . The first step of this analysis is PCR using biotin end-labeled primers and capture of the amplicons in streptavidin-coated microtitration wells. The two different alleles are determined by hybridization of the immobilized DNA using short allele-specific oligonucleotide probes (14-mer) labeled with europium (Eu) (22, 23) . In the present study, this technique was used to amplify a 69-nucleotide region around the 566 C3 T mutation of the FSHR gene using biotinylated primers. Thereafter, short allele-specific oligonucleotide probes were used in the hybridization reaction, quantified by time-resolved fluorometry based on fluorescence emission. The assay reliably classified the samples as homozygotes for the wild-type sequence, carrier heterozygotes, or mutation homozygotes. This simple single label hybridization assay is suitable for automation and analysis of a large number of DNA samples to detect specific point mutations. In the present study, this screening test was applied for determination of the frequency of the inactivating 566 C3 T mutation of the FSHR gene in four populations.
Materials and Methods

Sample preparation
A total of 1094 blood spot samples were collected consecutively and anonymously from the routine newborn screening cards (PKU cards) used for phenylketonuria and TSH screening in Denmark. From the eastern area of Switzerland, 1162 blood spot samples were collected randomly for the routine newborn screening for metabolic and endocrinological diseases. Another 540 blood spot samples were collected in Singapore from subjects of Chinese ethnic origin. The 1528 samples from the northern and eastern areas of Finland were obtained through the Finnish Red Cross (Helsinki, Finland). The samples were collected from consecutive blood donors for viral antibody testing (hepatitis and human immunodeficiency virus) and were prepared for PCR as described previously (24) . The 448 samples from the southwestern part of Finland were collected for newborn screening of the Finnish aspartylglucosaminuria mutation (13) and subjected to a rapid cell lysis procedure (25) . Samples were collected at random from both female and male donors. Positive and negative control blood spot samples were prepared using 60 L whole blood from subjects known to be homozygous or heterozygous for the FSHR mutation and from wild-type homozygotes. The samples were pipetted onto filter papers that were dried overnight in a fume hood and stored in plastic bags at 4 C until used. One 3-mm diameter blood spot disk from each filter paper card was punched out using a hand puncher. The blood disks were boiled in alkaline solution to liberate DNA (17) . Forty samples of isolated DNA and 35 blood spot samples were studied to validate the methodology. The collection of samples and the study protocol were approved by the local institutional review boards.
Oligonucleotides
Primers (WO594, WO595), probes (WO552, WO553), and target DNAs (WO548, WO549; Table 1 ) were synthesized using the PE Applied Biosystems model 392 DNA/ribonucleic acid synthesizer (Perkin Elmer, Foster City, CA) and phosphoramidate chemistry. All oligonucleotides were purified on 15% polyacrylamide urea gel using standard methods (26) . For biotinylation of the PCR primers, an aliphatic amino group was introduced at the 5Ј-end of the oligonucleotide using
-phosphoramidates were introduced at the 5Ј-end of the detection probe for labeling with Eu chelate.
Labeling of oligonucleotides with Eu chelate
The detection probes were labeled using Eu chelate W2014 (Wallac OY, Turku, Finland), which contains isothiocyanate as the reactive group. For this purpose, 50 g oligonucleotide were dissolved in 440 L sterile water, and the pH was adjusted to 10 with 1 mol/L Na 2 CO 3 . A 25-fold molar excess of the chelate per amino group was added (27) , and the reaction mixture was incubated overnight at room temperature. After labeling, the probes were purified on a Sephadex DNA grade G-50 column (Pharmacia Biotech, Uppsala, Sweden) using 10 mmol/L TrisHCl (pH 7.5), 50 mol/L ethylenediamine tetraacetate, and 50 mmol/L NaCl as elution buffer. The final probe contained 8 -11 Eu chelates/ oligonucleotide molecule. The degree of labeling of the detection probes was measured according to the method of Dahlén et al. (15) .
Biotinylation of oligonucleotides
For biotinylation, 50-g aliquots of oligonucleotides (WO594, WO595) were dissolved in 40 L water, and the pH was adjusted to 10 by adding 1 mol/L Na 2 CO 3 . Biotin-N-hydroxysuccinimide-ester (Sigma Chemical Co., St. Louis, MO) dissolved in N,N-dimethylformamide was added to the reaction to yield a 50-fold molar excess of active biotin per amino group. After overnight incubation at room temperature, free biotin was removed from the reaction mixture by using a NAP-5 and, subsequently, a NAP-10 column (Pharmacia Biotech). The biotinylation was verified using high performance liquid chromatography and a reverse phase column PEP RPC 5/5 (Pharmacia).
PCR amplification
A 69-bp fragment of exon 7 of the FSHR gene including nucleotide 566 was amplified using a pair of biotinylated primers. PCR amplification was performed in a PTC-200 Peltier Thermal Cycler (MJ Research, Inc., Watertown, MA) or Techne PHC-2 Dri-Block Cycle (Techne, Cambridge, Duxford, Cambridge, UK) using a program of 95 C for 1 min, 56 C for 2 min, and 72 C for 2 min for 35 cycles. About 100 ng isolated DNA or an unspecified amount of liberated DNA from the blood spots in a volume of 20 L supernatant, or a 3-mm diameter blood spot sample, were added to the reaction mixture. The final amplification reaction (50 L) contained 10 mmol/L Tris-HCl (pH 8.8), 1.5 mmol/L MgCl 2 for DNA samples/5 mmol/L MgCl 2 for blood spot samples, 300 mol/L of each deoxy-NTP, 50 mmol/L KCl, and 0.1% Triton X-100. The Taq DNA polymerase (DyNAZyme II, Finnzymes OY, Espoo, Finland) was added after the initial denaturation step using 1 U/reaction. PCR primers (Table 1) were used at 0.1 mol/L concentrations. Water instead of DNA was used as a control in each reaction to detect possible contamination. A sequence-verified DNA sample from a mutation homozygote, heterozygote, and wild-type homozygote were amplified in each PCR run as controls.
The Delfia oligonucleotide hybridization test for the FSHR
566
C3 T mutation
The assay flow chart is described in Fig. 1 . The analysis of the amplified DNA with time-resolved fluorescence was performed in two separate, allele-specific hybridization reactions in microtitration wells coated with streptavidin (SA). The Delfia assay buffer (Wallac) was added in a volume of 50 L, and 5 L of the PCR amplification product or oligonucleotide standard (10 L) were added in triplicate and incubated in SA-coated microtitration wells (Wallac). The wells were incubated at room temperature with shaking in a Delfia plateshaker (Wallac) for 1 h to capture the amplified DNA onto the surface of the microtitration wells. After collection, the well strips were washed three times at room temperature with Delfia wash solution (Wallac) in an automated Delfia platewasher (1296-024, Wallac). A 100-L volume of 50 mmol/L NaOH was added per well to denature the bound PCR product during an additional shaking for 5 min at room temperature. After denaturation, the wells were briefly washed with Delfia wash solution. The subsequent hybridization was performed in 100 L of the hybridization buffer (Delfia assay buffer with 1 mol/L NaCl and 0.1% Tween-20) containing 1 ng of the probe labeled with Eu chelate. One Eu-labeled probe (wild-type probe) was complementary to the wild-type DNA sequence and the other (mutant probe) to the mutated sequence. The hybridization was carried out for 3 h at room temperature. After hybridization, the wells were washed at 35 C using Delfia wash solution, and unbound probes were removed. For detection of the bound Eulabeled probes, 200 L Delfia enhancement solution (Wallac) were added to each microtitration well and shaken for 30 min at room temperature. Time-resolved fluorescence was measured in a fluorometer (ARCUS 1230 Fluorometer, Wallac). A signal ratio was first calculated from the amount of fluorescence detected for the normal (NP) and mutant (MP) probes after subtraction of the background signal, and then modified to logarithmic transformation because the signal ratio (NP/ MP) did not display normal distribution.
Restriction fragment length polymorphism (RFLP) and denaturing gradient gel electrophoresis (DGGE) analysis to detect the 566 C3 T mutation
To validate the methodology and to confirm the positive samples obtained during the screening, both RFLP and DGGE were used as control methods. For RFLP, genomic DNA was amplified by PCR as described above, and 20 L of the PCR product were digested with 20 U BsaMI (Promega Corp., Madison, WI) and electrophoresed through a 12% nondenaturing polyacrylamide gel. DNA was visualized with ethidium bromide (1). DGGE was used to detect the 566 C3 T mutation as described in our earlier studies (1).
Results
Sample preparation
All of the different sample materials, i.e. isolated DNA, blood cell lysates, supernatants of the blood spots, and dried blood spots, were suitable for the screening test. For practical reasons, cell lysates and dried blood spot samples were used in this study. The direct use of blood spot disks (3 mm) in PCR amplification with 5 mmol/L MgCl 2 reduces the number of experimental steps and would be preferable for large scale screening studies.
Optimization of the PCR amplification
The PCR was optimized for the amount of DNA, volume of supernatant (5-40 L), amount of Taq DNA polymerase, concentration of MgCl 2 (1.5-5 mmol/L), and number of PCR cycles (30, 35 , or 40 cycles; data not shown). Optimal DNA amplification and maximal hybridization signal were obtained with 100 ng isolated DNA, 5 L blood cell lysate, and 20 L supernatant from a blood spot, using 1 U Taq DNA   FIG. 1 . Principle of the Delfia assay for the 566 C3 T point mutation. The region around the mutation site is amplified by PCR, using biotinylated primers, from 100 ng genomic DNA or from an unknown amount of DNA from dried blood on filter paper discs with a 3-mm diameter. The PCR product is captured on SA-coated microtitration wells and analyzed in two separate, allele-specific hybridization reactions. In the single labeling assay format 14-mer europiumlabeled oligonucleotides are used, probe Eu 14 N is specific for normal, and probe Eu 14 M is specific for mutant allele. The samples can be defined as wild-type homozygous, carrier, or mutation homozygous based on fluorescence emission.
polymerase/PCR reaction, added after the initial denaturation step. The optimum PCR program was as follows: 95 C for 1 min, 56 C for 2 min, and 72 C for 2 min, for 35 cycles. The concentration of 1.5 mmol/L MgCl 2 was optimal for isolated DNA samples, and that of 5 mmol/L was optimal for the blood spot samples.
Optimization of oligonucleotide hybridization
The fragment of the FSHR gene containing the 566 C3 T mutation in exon 7 was amplified using a pair of biotinylated primers. Synthetic biotinylated target oligonucleotides (Table 1) for the wild-type and mutated FSHR gene were used to optimize the hybridization assay. The kinetic properties of the hybridization were studied for both capture and hybridization procedures. The highest signal was reached during 1-h capture reaction with shaking and a 3-h hybridization without shaking at room temperature. The amounts of hybridization probes (0.1, 0.5, 1, 1.5, 2, 5, and 10 ng/reaction) were tested by monitoring the signal to noise ratio (hybridization signal/unspecific signal) with a fixed amount of the synthetic target (1 ϫ 10 10 molecules/well). The optimal signal ratio was obtained at 1 ng/well. The optimal hybridization temperature was studied at the range of 4 -50 C, and the optimum occurred at room temperature. When the washing temperature was tested at 25-55 C, the best signal to crossreaction ratio was obtained at 35 C.
Assay validation
A total of 40 DNA samples and 35 dried blood spot samples were initially tested blindly to assess the accuracy of the hybridization assay. The results were clear cut after subtraction of the background signal from the original fluorescence. When the logarithmic signal ratio was calculated from the amount of fluorescence detected for the normal (NP) and mutant probes (MP), three different categories were clearly distinguished. The logarithmic signal ratio (NP/MP) was able to discriminate the three possible genotypes, namely wild-type homozygotes, heterozygotes, and mutation homozygotes. A log NP/MP ratio above 1 corresponded to a wild-type homozygote, a ratio between 1-0 corresponded to a heterozygote, and a ratio below 0 corresponded to a mutant homozygote (Fig. 2) . The test results of the 75 samples were in full agreement with earlier analyses of the same samples using DGGE and allele-specific RFLP. The technical details were described in our early studies (1, 4). There were 18 homozygotes, 27 carriers for the 566 C3 T mutation, and 30 wild-type homozygotes among the samples tested. During the population screenings (see below), we continued carrying out control analyses of the positive samples with RFLP and DGGE. We detected some false positive results in the samples from Denmark and Singapore Chinese, analyzed from blood spots (see Discussion). These samples were initially considered to represent mutation carriers, but were subsequently classified as wild-type homozygotes on the basis of the control analysis. No false negative results were observed during the assay validation.
Frequency of the mutation in four populations
Samples from four populations were analyzed to determine the frequency of the 566 C3 T transition in exon 7 of the FSHR gene ( Table 2 ). The results showed that the frequency of this mutation was clearly higher in the Finnish population than in samples received from Denmark, Switzerland, and Singapore Chinese. Excluding Finland, there was only one mutation carrier among the 2796 samples studied. This carrier was identified in a sample from Switzerland. In Finland, the geographic distribution of the 566 C3 T mutation was highly uneven (Fig. 3) . Of the 19 mutation carriers, only one was detected in the samples collected from the southwestern part of the country, whereas the others were all identified in samples collected from the northeastern regions. The birth places of the 30 obligatory mutation carriers (parents of tested patients) identified to date show the same geographical distribution (Fig. 3) .
Discussion
In previous studies, an inactivating point mutation ( 566 C3 T) of the FSHR gene was shown to be the cause of hypergonadotropic ovarian failure in a proportion of Finnish patients (1, 2) . Subsequent phenotypic studies in female and male homozygotes demonstrated ovarian failure with ovaries shown to contain oocytes but with arrest of follicular development in females (3), whereas the males showed vari- C3 T mutation of 75 DNA and dried blood spot samples. Based on the fluorescence signal from the hybridization assay of the Eu-labeled probes, the logarithmic signal ratio (normal probe/mutant probe) was calculated after subtraction of the background signal. The samples can be divided into 3 different categories by the log ratio indicating the FSHR gene status: wild-type, more than 1; heterozygous, 0 -1; and homozygous mutant, less than 0. able disturbance of spermatogenesis without azoospermia (4). The present study was initiated to study the carrier frequency of this mutation in Finland and other countries. For the detection of amplified target sequences, several methods are available. In large scale screening studies, automation combined with technical reliability, specificity, and nonradioactive signal detection methods are required. To achieve large scale population screening of the 566 C3 T mutation, we used a single label, allele-specific hybridization assay with time-resolved fluorometry as the signal detection system. In the initial validation of this method, 75 test samples were genotypically studied by this method, and the results were confirmed by RFLP analysis and/or DGGE.
There were no discrepancies among the results obtained by the three methods, and the results of the tested method showed clearly different values of logarithmic NP/MP ratio for each of the three genotypes. However, to confirm the study results, we also reanalyzed all positive samples detected in population screening. In this control testing, 8 false positive samples were identified. They had all been analyzed from blood spots and interpreted as carriers, although they were shown to be wild-type homozygotes upon control analysis (RFLP). This would have led to false interpretation of the carrier frequency if the positive results had not been additionally tested. In contrast, no false negative interpretations were made when studying either mutation homozygotes or heterozygotes. Therefore, the single label hybridization assay with time-resolved fluorometry can be considered a reliable screening method for mutations. Positive findings, however, have to be verified using an alternative method, such as RFLP, DGGE, or sequencing. The hybridization assay in combination with control analysis, as used in the present study, proved to be an effective method with high throughput in screening large numbers of samples for the FSH receptor 566 C3 T point mutation. On the population level, the results showed a carrier frequency of 0.96% for the mutation considering all samples from Finland, whereas its frequency in other populations was very low or could not be defined. This is in agreement with the findings in some other disease-causing genes that are enriched in Finland and underlie some of the 30 inherited diseases that are common in Finland but are uncommon elsewhere (28) . This pattern is caused by a combination of profound founder effects followed by genetic drift in a population expanding while isolated (29) . Instead, inbreeding, as known consanguineous marriages, is considered relatively uncommon in Scandinavian and Central European populations. In several of these disorders, this is also displayed as an enrichment of specific mutations in geographically defined subpopulations inside the country (30) . This typical feature is also displayed by the 566 C3 T mutation, which together with some other disorders, such as congenital chloride diarrhea (31) , shows a typical northeastern geographical enrichment. The fact that a specific mutation is enriched in Finland does not, however, exclude its presence in other populations. On the contrary, it is known that in some disorders, such as progressive myoclonus epilepsy, common mutations are shared with other populations (32) .
Based on the present results, however, it seems that the 566 C3 T mutation of FSHR is uncommon in other countries. The same is suggested by the recent study by Layman et al., who were not able to find this mutation in 35 patients with premature ovarian failure (33) . Therefore, it is most likely that in other populations, different mutations will be identified in the FSHR and other genes. Indeed, another heterozygous inactivating genomic point mutation was serendipitiously identified by Gromoll et al. (34) in a healthy female of German origin. However, no homozygotes for this mutation have been detected to date (35) . This indicates that other inactivating mutations in the FSHR gene are possible,
although not yet identified. Compared with the number of mutations identified to date in the LH receptor gene (36, 37) , the number of FSHR mutations is surprisingly low and not readily explicable. On the one hand, the obligatory infertility that the homozygous mutation causes in females should contribute to a low incidence in the genetic pool, unless heterozygosity for it has a selective advantage. On the other hand, the mild male phenotype of the homozygotes, with no absolute infertility, may contribute to preservation of the mutation. Nevertheless, it is likely that new FSHR mutations will be found in the future in other populations.
